Aeterna Zentaris Inc (AEZS)

0.4000
-0.0311(-7.21%)
After Hours
0.4000
0.0000(0.00%)
- Real-time Data
  • Volume:
    2,192,521
  • Bid/Ask:
    0.3951/0.4000
  • Day's Range:
    0.3968 - 0.4399

AEZS Overview

Prev. Close
0.4311
Day's Range
0.3968-0.4399
Revenue
4.16M
Open
0.4361
52 wk Range
0.356-3.59
EPS
-0.07
Volume
2,192,521
Market Cap
48.56M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,152,826
P/E Ratio
-
Beta
1.77
1-Year Change
-5.26%
Shares Outstanding
121,397,007
Next Earnings Date
Mar 02, 2022
What is your sentiment on Aeterna Zentaris Inc?
or
Market is currently closed. Voting is open during market hours.

Aeterna Zentaris Inc Company Profile

Employees
12
Market
Canada

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Sale una nueva variante y no veas la k se lía
    0
    • why is this 🚀?
      0
      • There is hype on new COVID treatment announcement and it is/was oversold
        0
    • Seeing a lot of predictions for 3.50 in the next few days
      0
      • why?
        0
    • let's get that oral vaccine out
      1
      • Than ?
        0
        • It's spelled -ess h eye tee-
          1
          • I used to be an enthusiastic bag holder too,...,woke up,dumped the ****
            0
            • https://www.handelsblatt.com/dpa/wirtschaft-handel-und-finanzen-verband-corona-impfstoffe-zweiter-generation-vielleicht-schon-2021/27222440.html?ticket=ST-5153637-HIXgEEndEVksGk2n6CrC-ap2
              0
              • https://www.zentaris.com/oral-coronavirus-vaccine
                0
                • I want to dump my position of this garbage as soon as possible. Been holding since right after the run up in Feb., got in low, but, I don't care. They could have a PR that announced they found a cure for both aging and cancer, and their share price would still be ********
                  1
                  • Financials are not favorable, but for some reason I'm considering a risk on this one.
                    0
                    • use a real name, ****
                      0
                  • awesome quarter
                    0
                    • It managed to outperform the Markets overall today, if we are willing to accept sideways as an outperform.
                      0
                      • well done aezs
                        0
                        • Rename it "Sideways International Inc."
                          0
                          • fantastic company
                            0
                            • Preclinical trials will likely be completed first. AEZS would then identify the Lead Candidate. An new drug application (IND) would then likely be submitted to the FDA. Once the IND is approved, then Phase 1 trials should begin. When the IND is submitted, the company should announce this to shareholders. Once the IND is approved, this should also be announced to shareholders.
                              0
                              • I think the company will go through Germany's FDA and not the USA one
                                0
                              • Probably both as US & EU has friendly relations. The thing is, they need to speed up a bit to normalized the global pandemic.
                                0
                            • Any thoughts on when the Covid application was submitted. I assume at the same time Aezs signed the license agreement with the uni. Typical response from the gov. Agency for trials is around two months. That puts us around middle of May. Please intelligent comments.
                              0
                              • The next VXRT...........Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
                                0
                                • https://www.eurekalert.org/pub_releases/2021-04/uow-cdf042721.php
                                  0
                                  • https://www.eurekalert.org/pub_releases/2021-04/uow-cdf042721.php
                                    0
                                    • I agree 100%
                                      0
                                      • Some sort of upbeat PR would be awfully nice to get this ***up on its feet, been laying here and descending for the past two months,...,uhg.
                                        0
                                        • POS
                                          0
                                      • This company sucks. it was a nice PR piece on the vaccine, but until they actually roll out something and stop wasting investor money, its going to $.01
                                        2
                                        • It would be nice if Citadel would stop manipulating share prices, wouldn't it ?.
                                          0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.